Alpha Cognition, Inc.

Alpha Cognition is a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer&s;s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer&s;s type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS.